Ozempic's Potential in Combating Alcohol Use Disorder Uncovered

In a small trial, Novo Nordisk's diabetes drug Ozempic showed promise in reducing alcohol consumption and cravings in individuals with alcohol use disorder. Participants treated with Ozempic displayed a significant reduction in alcohol intake compared to those given a placebo. Researchers stress the need for larger studies.

Novo Nordisk’s widely used diabetes medication, Ozempic, has shown potential beyond its intended use, exhibiting significant impact on alcohol use disorder, researchers announced Wednesday.

In a small-scale study involving 48 participants, those administered Ozempic demonstrated a marked reduction in alcohol consumption during controlled sessions, a result not mirrored in the placebo group. This finding, published in JAMA Psychiatry, highlights Ozempic's effect in tempering weekly alcohol cravings.

The drug's main component, semaglutide, also appears capable of reducing heavy drinking days. While this outcome is promising, Klara Klein from the University of North Carolina emphasizes the necessity for more extensive trials. As Ozempic undergoes testing for other health applications, such as cardiovascular and sleep-related disorders, these preliminary results could signal a broader therapeutic horizon.